EP1737824A2 - Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel - Google Patents

Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel

Info

Publication number
EP1737824A2
EP1737824A2 EP05732062A EP05732062A EP1737824A2 EP 1737824 A2 EP1737824 A2 EP 1737824A2 EP 05732062 A EP05732062 A EP 05732062A EP 05732062 A EP05732062 A EP 05732062A EP 1737824 A2 EP1737824 A2 EP 1737824A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
phenyl
mmol
group
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05732062A
Other languages
German (de)
English (en)
French (fr)
Inventor
Dirk Stenkamp
Stephan Georg Mueller
Philipp Lustenberger
Thorsten Lehmann-Lintz
Gerald Jürgen Roth
Marcus Schindler
Leo Thomas
Ralf R. H. Lotz
Klaus Rudolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1737824(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of EP1737824A2 publication Critical patent/EP1737824A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • New alkyne compounds having MCH antagonist activity and medicaments containing these compounds are described in detail below.
  • the present invention relates to novel alkyne compounds, their physiologically acceptable salts and their use as MCH antagonists and their use for the preparation of a medicament which is used for the prophylaxis and / or treatment of phenomena and / or diseases caused by MCH or with MCH are in a different causal relationship, is appropriate.
  • Another object of this invention relates to the use of a compound according to the invention for influencing the eating behavior as well as for reducing the body weight and / or for preventing an increase in the body weight of a mammal.
  • compositions and pharmaceutical compositions, each containing a compound of the invention, as well as processes for their preparation are the subject of this invention. Further objects of this invention relate to processes for the preparation of the compounds according to the invention.
  • obesity often leads to other diseases, such as diabetes, dyslipidaemia, high blood pressure, arteriosclerosis and coronary
  • obesity refers to an excess of adipose tissue in the body.
  • obesity is considered to be any elevated level of body fat, leading to a health risk. There is no sharp separation between normal weight and obese individuals, but it does increase Obesity-related health risks are likely to increase continuously with increasing obesity.
  • BMI body mass index
  • the individuals having a body mass index (BMI) defined as the kilogram of body weight divided by height (in meters) squared are above the value of 25, especially above 30, when considered suffering from obesity.
  • MCH antagonists inter alia WO 01/21577, WO 01/82925.
  • MCH Melanin-concentrating hormone
  • Rhodopsin-related GPCRs mediate MCH receptors 1 and 2 (MCH-1R, MCH-2R).
  • the MCH-1 R antagonist SNAP-7941 provides further anxiolytic and antidepressant effects in behavioral experiments with rats [3].
  • the MCH-MCH-1 R system is involved not only in the regulation of the energy balance but also the affectivity.
  • WO 01/82925 also compounds of the formula in which Ar 1 is a cyclic group, X and Y spacer groups, Ar is an optionally substituted condensed polycyclic aromatic ring, R 1 and R 2 are independently H or a hydrocarbon group, wherein R 1 and R 2 together with the adjacent N Atom can form an N-containing heterocyclic ring and R 2 together with the adjacent N-atom and Y can form an N-containing hetero ring, described as MCH antagonists for the treatment of, inter alia, obesity.
  • Y, A and B may denote cyclic groups and X, Z and W may represent bridges or bonds, as MCH antagonists.
  • Y, A and B may denote cyclic groups and X, Z and W may represent bridges or bonds, as MCH antagonists.
  • MCH antagonists MCH antagonists.
  • the following substances are also mentioned: (1- ⁇ 5- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidin-3-yl) -dimethyl-amine, 5 '_ [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl-3-pyrrolidin-1-yl-3,4,5,6-tetrahydro-2H- [1, 2'] bipyridinyl,
  • WO 04/039764 A1 discloses amide compounds of the formula I.
  • the present invention has for its object to show new alkyne compounds, especially those which have a particularly high activity as MCH antagonists. It is also an object of this invention to provide novel alkyne compounds which allow to influence mammalian eating habits and, in particular in mammals, to achieve a reduction in body weight and / or to prevent an increase in body weight.
  • Medicaments for the treatment of metabolic disorders such as obesity and / or diabetes as well as diseases and / or disorders associated with obesity and diabetes.
  • Other objects of the present invention relate to
  • a first subject of the present invention are alkyne compounds of general formula I.
  • R 1 , R 2 independently of one another are H, C n . 8- alkyl, C 3 . 7 -cycloalkyl or an optionally with the same or different radicals R 20 mono- or polysubstituted and / or with nitro monosubstituted phenyl or pyridinyl, wherein the alkyl or cycloalkyl group with the same or different radicals R 11 mono- or polysubstituted can, and where a -CH 2 - Group in position 3 or 4 of a 5, 6 or 7-membered cycloalkyl group may be replaced by -O-, -S- or -NR 13 -, or
  • alkylene bridge may be substituted with one or two identical or different carbo- or heterocyclic groups Cy such that the bond between the alkylene bridge and the group Cy
  • Cie-alkylene bridge containing one or more substituents independently selected from fluoro, chloro, hydroxy, cyano, CF 3, C M alkyl, hydroxy-C ⁇ alkyl, C 3 - 6 cycloalkyl, and C. 1 4- alkoxy, wherein two alkyl substituents to form a C 3 . 7 -Cycloalkyl group may be joined together, or
  • a C 1-4 -alkyleneoxy or C 1-4 -alkyleneimino bridge where the imino group may be substituted by a C 1-4 -alkyl group, and in which the alkylene unit has one or more substituents selected independently of one another from fluorine, chlorine, CF 3 , hydroxyC ⁇ alkyl, C ⁇ alkyl and C 3 . 6 - having cycloalkyl, wherein two alkyl groups to form a C 3 . 7 - cycloalkyl group or if an alkyl group is connected to the imino group, also forming a cyclo-C 4 . 6 -alkyleneimino group may be joined together, or a C 3 .
  • 6- alkenylene or C 3 . 6- alkynylene bridge which is unsubstituted or one or more substituents independently selected from fluorine, chlorine, CF 3 , hydroxy-C ⁇ -alkyl, C ⁇ -alkyl and C 3 . 6 -cycloalkyl, wherein two alkyl substituents to form a C 3 - 7 -cycloalkyl or C 5 . 7 -Cycloalkenyl group may be joined together, and
  • W, Z independently of one another are a single bond or a C 2 -alkylene bridge
  • Y, A are independently selected from the group of the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, benzimidazolyl, benzoxazolyl , Chromanyl, chromen-4-onyl, thienyl, furanyl, benzothienyl or benzofuranyl, wherein the cyclic groups mentioned one or more times to one or more carbon atoms having the same or different radicals R 20 , in the case of a phenyl ring also additionally simply with nitro , and / or
  • B is as defined for Y, A or C ⁇ - 6 -alkyl,. 6- alkenyl, C
  • Cy is a carbo or heterocyclic group selected from one of the following meanings - a saturated 3- to 7-membered carbocyclic group, - an unsaturated 4- to 7-membered carbocyclic group, - a phenyl group, - a saturated 4-7 a saturated or unsaturated 5- to 7-membered heterocyclic group having an N, O or S atom as a heteroatom, - a saturated or unsaturated 5- to 7-membered heterocyclic group having two or more N atoms or with one or more two N atoms and an O or S atom as heteroatoms, - an aromatic heterocyclic 5- or 6-membered group having one or more identical or
  • R 11 is halogen, C, - 6 alkyl, C 2nd 6 alkenyl, C 2 . 6- alkynyl, R 15 -O-, R 15 -O-CO-, R 15 -CO-O-, cyano, R 16 R 17 N-, R 8 R 19 N-CO- or Cy-, where in the previously specified groups one or more C atoms independently of one another by substituents selected from halogen, OH, CN, CF 3 , C ⁇ -Alky !, hydroxy-C - be substituted alkyl;
  • R 13 is one of the meanings given for R 17 .
  • R 14 is halogen, cyano, C 1-4 alkyl, C 2 . 6 alkenyl, C 2 . 6- alkynyl, R 5 -O-, R 15 -O-CO-, R 15 -CO-, R 15 -CO-O-, R 16 R 17 N-, R 18 R 19 N-CO-, R ⁇ -OC ⁇ -alkyl, R 5 -O-CO-C ⁇ -alkyl, R 15 -SO 2 -NH-, R 15 -O-CO-NH-C ⁇ -alkyl-, R ⁇ -SO ⁇ NH-ds -alkyl, R 5 -CO-d- 3- alkyl, R ⁇ -CO-OC ⁇ -alkyl, R 16 R 17 NC.,. 3- alkyl, R 1, R 2, N-CO-C 1 -alkyl- or cy-C 1-3 -alkyl,
  • R 15 is H, d-4 alkyl, C 3-7 cycloalkyl, C. 3 7 -cycloalkyl-C 1-3 -alkyl, phenyl, phenyl-d- 3 -alkyl, pyridinyl or pyridinyl-d- 3- alkyl,
  • R 16 is H, C 1 -e-alkyl, C 3 . 7 cycloalkyl, C 3-7 cycloalkyl-d- 3 -alkyl, C. 4 7 cycloalkenyl, C 4 . 7 - Cycloalkenyl-C ⁇ - 3 -alkyl, ⁇ -hydroxy-C 2 . 3 -alkyl, ⁇ - (C ⁇ - 4- alkoxy) -C 2 - 3 -alkyl ! Amino C 2 - 6 -alkyl, C ⁇ -alkyl-amino-C ⁇ alkyl, di (C 1-4 -alkyl) -amino-C. 2 6 -alkyl or cyclo-C 3 . 6 -alkyleneimino-C 2 . 6 -alkyl-, • * ⁇ ⁇ ⁇
  • R 17 is one of the meanings given for R 16 or phenyl, phenyl-D- 3- alkyl, pyridinyl, C ⁇ . -Alkylcarbonyl, hydroxycarbonyl-C ⁇ - 3 -alkyl, d. 4 -alkoxycarbonyl, C 1-4 -alkoxycarbonyl-C. 1 3 alkyl, C M alkyl-carbonylamino-ds-alkyl, N- (C ⁇ - 4 -alkylcarbonyl) -N- (C 1-4 -alkyl) -amino-C.
  • R 18 , R 19 are independently H or d. 6- alkyl
  • R 20 is halogen, hydroxy, cyano, d- 6 -alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-Ct-C3 alkyl, hydroxy D 3 -alkyl, R 22 -d- 3- alkyl or one of the meanings given for R 22 , R 21 d- alkyl, ⁇ -hydroxy-C 2 . 6 -alkyl, ⁇ -C 1 _ 4 -alkyl-amino-C 2 . 6 alkyl, ⁇ -di- (C 1-4 -alkyl) -amino-C.
  • the H atom of an existing carboxy group or an H atom bound to an N atom can each be replaced by a residue which can be split off in vivo,
  • the compounds according to the present invention have a particular antagonist activity compared to known, structurally comparable compounds. of the MCH receptor, particularly the MCH-1 receptor, and show very good affinities in MCH receptor binding studies.
  • the compounds of the invention have a high to very high selectivity with respect to the MCH receptor.
  • the compounds according to the invention have low toxicity, good oral absorbability and intracerebral transitivity, in particular cerebral activity.
  • the invention also relates to the respective compounds in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates, in the form of tautomers and in the form of the free bases or the corresponding acid addition salts with0 pharmacologically acceptable acids. Also included in the subject matter of this invention are the compounds of the invention, including their salts, in which one or more hydrogen atoms are replaced by deuterium.
  • physiologically acceptable salts of the alkyne compounds according to the invention described above and below 5 are also an object of this invention.
  • compositions comprising at least one alkyne compound according to the invention and / or a salt according to the invention tro0 in addition to optionally one or more physiologically acceptable excipients.
  • medicaments comprising at least one alkyne compound according to the invention and / or an inventive salt in addition to optionally one or more inert carriers and / or diluents are the subject of the present invention.
  • an object of this invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for influencing the eating behavior of a mammal.
  • an object of the present invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the production of a medicament with MCH receptor antagonistic activity, in particular with MCH-1 receptor antagonistic activity.
  • an object of this invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the preparation of a medicament, which for the prophylaxis and / or treatment of phenomena and / or diseases caused by MCH or with MCH in one other causal relationship is appropriate.
  • Another object of this invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the manufacture of a medicament, which for the prophylaxis and / or treatment of metabolic disorders and / or eating disorders, in particular obesity, bulimia, bulimia nervosa, cachexia , Anorexia, anorexia nervosa and hyperphagia, is suitable.
  • an object of this invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the preparation of a medicament which is used for the prophylaxis and / or treatment of obesity-related diseases and / or disorders, in particular diabetes, especially type II Diabetes, diabetic complications, including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, especially arteriosclerosis and hypertension, arthritis and gonitis.
  • diabetes especially type II Diabetes, diabetic complications, including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, especially arteriosclerosis and hypertension, arthritis and gonitis.
  • the present invention has the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the preparation of a medicament which is used for the prophylaxis and / or treatment of hyperlipidemia, cellulitis, fat accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, affective disorders, Depression, anxiety,
  • the subject of the study is sleep disorders, reproductive disorders, sexual disorders, memory disorders, epilepsy, forms of dementia and hormonal disorders.
  • a further subject of this invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the preparation of a medicament which is suitable for the prophylaxis and / or treatment of voiding disorders, such as urinary incontinence, overactive bladder, urinary urgency, nocturia and enuresis ,
  • the subject of the present invention is the use of at least one alkyne compound according to the invention and / or a salt according to the invention for the production of a medicament which is suitable for the prophylaxis and / or treatment of dependencies and / or withdrawal symptoms.
  • an object of this invention relates to processes for the preparation of a medicament according to the invention, characterized in that at least one alkyne compound according to the invention and / or a salt according to the invention is incorporated into one or more inert carriers and / or diluents by non-chemical means.
  • a further subject of this invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a first active ingredient selected from the alkyne compounds and / or the corresponding salts, and a second active ingredient selected from the group consisting of active ingredients for the treatment of diabetes, drugs for the treatment of diabetic complications, drugs for the treatment of obesity, preferably other than MCH antagonists, drugs for the treatment of hypertension, drugs for the treatment of Dyslipidemia or Hyperlipidemia, including arteriosclerosis, drugs for the treatment of arthritis, drugs for the treatment of anxiety and drugs for the treatment depression, optionally with one or more inert carriers and / or diluents.
  • an object of this invention relates to a process for the preparation of alkyne compounds of the formula A.5
  • R 1 , R 2 , X, Y, W, A and B have one of the meanings given above and below,
  • Hal is chlorine, bromine or iodine, preferably bromine or iodine, with an alkyne compound of the formula A.2
  • Another object of this invention is a process for the preparation of alkyne compounds of formula B.5
  • R 1 R 2 NXYZC ⁇ CAB (B.5) where in the formulas B.1, B.2, B.3, B.4 and B.5 R, R 2 , X, Y, Z, A and B have one of the meanings given above and below,
  • Hal is chlorine, bromine or iodine, preferably bromine or iodine, with an alkyne compound of the formula B.2
  • an object of this invention relates to a process for the preparation of alkyne compounds of the formula C.3
  • R 1 , R 2 , X, Y, W, A and B have one of the meanings given above and below,
  • Hal is chlorine, bromine or iodine, preferably bromine or iodine, with an alkyne compound of the formula C.2
  • Another object of this invention is a process for the preparation of alkyne compounds of the formula D.3
  • R 1 , R 2 , X, Y, Z, A and B have one of the meanings given above and below,
  • Hal is chlorine, bromine or iodine, preferably bromine or iodine, with an alkyne compound of the formula D.1
  • radicals and / or substituents in a compound may each have the same or different meanings given.
  • R 1 and R 2 are not connected to one another via an alkylene bridge, then R 1 and R 2 independently represent preferably an unsubstituted or a mono- 11 with identical or different radicals R or more C 8 substituted alkyl or C. 3 7 -cycloalkyl group, wherein a -CH 2 group in position 3 or 4 of a 5, 6 or 7-membered cycloalkyl group may be replaced by -O-, -S- or -NR 13 -, or optionally with the same or various radicals R 20 mono- or polysubstituted and / or nitro single-substituted phenyl or pyridinyl, and wherein one or both of the radicals R 1 and R 2 may also be H.
  • R 11 Preferred meanings of the radical R 11 here are F, Cl, Br, d. 6- alkyl, C 2 . 6 alkenyl, C 2 . 6 - alkynyl, R 15 -O-, cyano, R 16 R 17 N-, C 3 . 7 -cycloalkyl, cycio-C 3 . 6 -alkylenimino-, pyrrolidinyl, N- (d- C4 alkyl) -pyrrolidinyl, piperidinyl, N- (C 1.
  • alkyl) -piperidinyl, phenyl and pyridyl where a in the above-mentioned groups and radicals or more C -Atoms independently one or more times with F, C-
  • 3- alkyl or hydroxy-d- 3- alkyl, and / or one or two C atoms may be independently substituted with CI, Br, OH, CF 3 or CN, and wherein the aforementioned cyclic groups one or more times at one or more carbon atoms with the same or different radicals R 20 , in the case of a phenyl group may also be additionally substituted with nitro, and / or one or more NH groups with R 21 .
  • R 11 is one of the meanings R 15 -O-, cyano, R 16 R 17 N- or cyclo-C 3 . 6 -alkyleneimino-, preferably the R 1 -substituted C atom of the alkyl or cycloalkyl group is not directly linked to a heteroatom, such as the group -NX-.
  • the radicals R 1 , R 2 are independently H, C ⁇ . 6- alkyl, C 3 . 5 alkenyl, C 3 . 5 alkynyl, C 3-7 cycloalkyl, hydroxy-C. 3 cycloalkyl, C 3 . -CycIoalkyl-C ⁇ . 3 alkyl, (hydroxy-C 3 H 7 -, cycloalkyl) -d.
  • Phenyl group may additionally be additionally substituted with nitro, and / or one or more NH groups with R 21 .
  • Preferred substituents of the above-mentioned phenyl or pyridyl are selected from the group F, Cl, Br, I, cyano, d- 4 -alkyl,. Alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C 3 -alkylamino, di (C 1 -3 -alkyl) amino, acetylamino, aminocarbonyl, difluoromethoxy, trifluoromethoxy, amino -C ⁇ - 3 alkyl,
  • radicals R 1 and / or R 2 are selected from the group consisting of H, d- C4 alkyl, hydroxy-d- 4 alkyl, C 3-5 alkenyl, C. 3 5- alkynyl, C 3 . 7 - Cy oalkyl, hydroxy-C 3 - 7 -cycloalkyl, dihydroxy-C 3 - 6 -alkyl, C 3 . 7 -cycloalkyl-d- 3- alkyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, (hydroxy-C 3 - 7 -cycloalkyl) -d.
  • R 1 and / or R 2 are selected from the group consisting of H, methyl, ethyl, n-propyl, i-propyl, prop-2-enyl, but-2-enyl, prop-2-ynyl, But-2-ynyl, 2-methoxyethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclopropylmethyl,
  • Cyclopentylmethyl hydroxy-C 3 - 7 -cycloalkyl, (hydroxy-C 3 -alkyl) -hydroxy-C 3 . 7 cycloalkyl, dihydroxy-C 3-5 alkyl, (. 1-hydroxy-C 3 6 cycloalkyl) -methyl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl and Pyridyl, where said groups may be mono- or polysubstituted by F and / or D- 3 alkyl, and wherein the phenyl and pyridyl rings may be substituted as indicated.
  • R 1 and / or R 2 are therefore H, methyl, ethyl, n-propyl, i-propyl, prop-2-enyl, prop-2-ynyl, 2-methoxyethyl, cyclopropyl, cyclopentyl, cyclohexyl, Cyclopropylmethyl, cyclopentylmethyl, hydroxycyclopentyl, hydroxycyclohexyl, (hydroxymethyl) -hydroxy-cyclopentyl, (hydroxymethyl) -hydroxy-cyclohexyl, 2,3-dihydroxypropyl, 2-hydroxy-1- (hydroxymethyl) -ethyl, 1,1- Di (hydroxymethyl) ethyl, (1-
  • At least one of the radicals R 1 , R 2 has a meaning other than H.
  • R 1 and R 2 form an alkylene bridge
  • the previously defined alkylene bridge with a carbo- or heterocyclic group Cy may be substituted such that the bond between the alkylene bridge and the group Cy via a single or double bond, via a common carbon atom to form a spirocyclic ring system, via two common, adjacent C and / or N atoms to form a fused bicyclic ring system or via three or more C and / or N atoms to form a bridged ring system takes place.
  • R 1 and R 2 form an alkylene bridge such that R 1 R 2 N- represents a group selected from azetidine, pyrrolidine, piperidine, azepane, 2,5-dihydrid-1 H-pyrrole, 1, 2,3,6-tetrahydro-pyridine, 2,3,4,7-tetrahydro-1H-azepine, 2,3,6,7-tetrahydro-1H-azepine, piperazine, wherein the free imine function with R 13 substituted is, piperidin-4-one, morpholine and thiomorpholine,
  • pyrrolidine is particularly preferably selected from pyrrolidine, piperidine, piperazine, in which the free imine Function substituted with R 3 , and morpholine,
  • one or more H atoms may be replaced by identical or different R 14 radicals and / or the abovementioned groups in a manner specified in the general definition of R 1 and R 2 with one or two identical or different carbo- or heterocyclic Cy groups may be substituted, wherein the Cy group may be mono- or polysubstituted with R 20 .
  • Particularly preferred groups Cy here are C 3 . 7 -cycloalkyl, aza-C 4 - 7 -cycloalkyl, in particular cyclo-C 3 . 6 -alkylenimino-, and 1-d ⁇ -alkyl-aza-d- ⁇ -cycloalkyl-, where the group Cy may be mono- or polysubstituted with R 20 .
  • the C 3 -C 8 -alkylene bridge formed by R 1 and R 2 in which -CH 2 groups may be replaced as indicated, may be substituted as described with one or two identical or different carbo- or heterocyclic groups Cy which may be substituted as indicated above.
  • Cy is preferably selected from the group consisting of C 3 . 7 -cycloalkyl, cyclo-Q ä - ⁇ -alkylenimino, 1 H-imidazole, thienyl and phenyl.
  • Cy is preferably selected from the group consisting of C 3 . 7 -cycloalkyl, aza-C. 8 -cycloalkyl, oxa-C. 8 - cycloalkyl-, 2,3-dihydro-1H-quinazolin-4-one.
  • Cy is preferably selected from the group consisting of C 4 . 7 - cycloalkyl, phenyl, thienyl.
  • Cy is preferably C 4 . 8 -cycloalkyl or aza-C 4 . 8 -cycloalkyl.
  • the group Cy is preferably linked via a single bond to the group R 1 R 2 N-, wherein Cy is preferably selected from the group consisting of C 3 - 7 cycloalkyl, and cyclo C 3 - 6 -alkylenimino-, these groups being as specified, preferably by fluorine, CF 3, d_ 3 alkyl, hydroxy-d- 3 may be substituted alkyl, and hydroxy.
  • the group is particularly preferred a meaning according to one of the following sub-formulas
  • heterocycle formed by the group R 1 R 2 N- by one or two, preferably a C 3 . 7 -cycloalkyl group may be substituted, wherein the cycloalkyl group may be mono- or polysubstituted by R 20 , and
  • ring connected to the heterocycle formed by the group R 1 R 2 N- may be monosubstituted or polysubstituted on one or more C atoms with R 20 , and in the case of a phenyl ring may additionally also be substituted simply by nitro, and
  • the substituents R 20 are independently preferably C ⁇ alkyl, d- 4 alkoxy C ⁇ . 3 -alkyl, hydroxy-C. 3 -alkyl, hydroxy, fluorine, chlorine, bromine or CF 3 , in particular hydroxy.
  • heterocycle formed by the group R 1 R 2 N- with C 3 . 6 -cycloalkyl, hydroxy-C 3 . 6 - may be substituted cycloalkyl or (hydroxy-C 3 - 6 -cycloalkyl) -d- 3- alkyl, and
  • heterocycle formed by the group R 1 R 2 N- may be mono-, di- or trisubstituted by identical or different radicals R 14 .
  • the substituents R 14 means in this case preferably independently of each other F, CI, Br, OH, d- C4 alkyl, d- 4 alkoxy, C ⁇ - 4 alkoxy-3 C ⁇ - alkyl, hydroxy-C ⁇ alkyl, or CF 3 , in particular hydroxy, C 3 -alkyl, CF 3 or hydroxy-C 3 -alkyl.
  • R 1 R 2 N hydroxypyrrolidinyl, hydroxypiperidinyl, 3,4-dihydroxypyrrolidinyl, 3,4-dihydroxypiperidinyl, 3,5-dihydroxypiperidinyl, (hydroxymethyl) -pyrrolidinyl , (Hydroxymethyl) piperidinyl, (hydroxymethyl) -hydroxy-pyrrolidinyl, (hydroxymethyl) -hydroxy-piperidinyl,
  • a hydroxymethyl group on the carbon atom may be mono- or disubstituted by methyl, wherein two methyl substituents may be joined together to form a cyclopropyl group, and wherein in one or two hydroxy groups, the H atom may be replaced by a methyl group, and
  • methyl or ethyl groups may be mono-, di- or trisubstituted by fluorine, and in which one or more carbon-bonded hydrogen atoms of the heterocycle formed by the group R 1 R 2 N- independently of one another by fluorine, chlorine, CN, CF 3 , d-3-alkyl, hydroxy-C 3 -alkyl > in particular C 3 -alkyl or CF 3 , preferably methyl, ethyl, CF 3 may be substituted.
  • R 14 the following definitions of the substituent R 14 are preferred: F, Cl, Br, cyano, d-4 alkyl, C 2nd - alkenyl, C ⁇ -Alkinyi, C 3 7 cycloalkyl, C. 3 7 -cycloalkyl-d- 3- alkyl, hydroxy, hydroxy-d. 3- alkyl, d- 4 alkoxy, ⁇ - (C 1.
  • alkoxy) -C ⁇ - 3 alkyl C ⁇ alkyl-carbonyl, carboxy, d- alkoxycarbonyl, hydroxy-carbonyl-d-3 alkyl , 4- alkoxycarbonyl-C 1-3 -alkyl, C 1-4 -alkoxycarbonylamino, d.
  • substituent R 14 are F, CI, Br, C ⁇ - 4 alkyl, hydroxy, hydroxy-3 C ⁇ - alkyl, d- 4 alkoxy, ⁇ - (d- 4 -alkoxy) -C 1-3 alkyl, amino-C ⁇ - -aikyl- 3, C 1-4 - alkyl-amino-d-3 alkyl, C 3 - 7 -cycloalkyl-amino-d-3-alkyl, N- (C.
  • one or more C atoms may in each case additionally be monosubstituted or polysubstituted with F and / or in each case one or two C atoms independently additionally simply substituted by CI or Br.
  • preferred meanings of R 14 include -CF 3 , -OCF 3 , CF 3 -CO-, and CF 3 -CHOH-.
  • substituent R 14 are d. 3- alkyl, hydroxy-C 1-3 -alkyl, methoxymethyl, hydroxy, CF 3 , CF 3 -CHOH-, especially hydroxy, methyl, ethyl, CF 3 and hydroxymethyl.
  • the bridge X is, as defined above or below, alkyleneoxy or alkyleneimino, then the bridge is oriented in such a way that the heteroatom is connected to the group Y. If the bridge X is an alkenylene group, then the double bond is not directly connected to the group R 1 R 2 N.
  • alkylene group in the group X in the meanings alkylene, alkyleneoxy, alkylimino and alkenylene is unbranched without the specified substituents.
  • the bridge X is a Cie-alkylene bridge, in particular a C 2 - 4 -alkylene bridge, the one, two, three or a plurality, preferably one, two or three substituents independently selected from fluorine, chlorine, cyano, CF 3 , hydroxy, C- M- alkyl, hydroxy-C ⁇ -alkyl, C 3 - 6 - cycloalkyl and C ⁇ -alkoxy, preferably selected from d. 3 alkyl and cyclopropyl, wherein two alkyl substituents to form a C 3 . 7 -Cycloalkyl group may be joined together.
  • the bridge X is preferably a propylene bridge, which may be substituted as indicated.
  • the alkylene bridge has 1, 2 or 3 substituents. preferred
  • Substituents here are fluorine, chlorine, hydroxy, d. 3 alkyl and cyclopropyl, especially C 3 alkyl, and cyclopropyl, wherein two alkyl substituents to form a C. 3 6 - cycloalkyl group may be joined together.
  • the bridge X is a C ⁇ alkyleneoxy-bridge, in particular a C 2 - 3 alkyleneoxy bridge containing 1, 2, 3 or more, preferably one, two or three substituents independently selected from fluorine, CF 3, d 4 -alkyl, hydroxy-C ⁇ alkyl and C 3 - 6 cycloalkyl, preferably selected from d- C3 alkyl and cyclopropyl, said two alkyl substituents to form a C 3-7 -Cycloalkyl group can be linked together.
  • the bridge X is preferably an ethyleneoxy bridge which may be substituted as indicated.
  • the alkylene unit has 1, 2 or 3 substituents.
  • preferred alkylene unit has 1, 2 or 3 substituents.
  • Substituents in this case fluorine, d- C3 alkyl and cyclopropyl, in particular methyl, ethyl and i-propyl, where two alkyl substituents to form a C. 3 6 -Cycloalkyl group, in particular a cyclopropyl group, may be joined together.
  • the bridge X is a C ⁇ -Alkylenimino bridge, in particular a C 2 ⁇ -Alkylenimino bridge, in which the imino group may be substituted by a C alkyl group, and wherein the alkylene unit is 1, 2, 3 or more, preferably one, two or three, independently selected from fluoro, CF 3 , d-4-alkyl, hydroxy-d 4 -alkyl and C 3 . 6 -cycloalkyl, preferably selected from d. 3 alkyl and cyclopropyl, wherein two alkyl groups to form a C 3 .
  • the imino group is preferably unsubstituted or has a d, 3- alkyl substituent, preferably a methyl group.
  • the bridge X is preferably an ethyleneimino bridge, which may be substituted as indicated.
  • the alkylene unit has 1, 2 or 3 substituents.
  • Preferred substituents here are fluorine, d- C3 alkyl and cyclopropyl, in particular methyl, ethyl and i-propyl, where two alkyl substituents to form a C 3 - 6 cycloalkyl group, especially a cyclopropyl group, or if an alkyl Group linked to the imino group may also be linked together to form a pyrrolidine or piperidine group.
  • the bridge X represents a C 3 . 6 alkenylene bridge, in particular a Cs ⁇ alkenylene bridge, which is unsubstituted or one, two, three or more, preferably one, two or three substituents selected independently from fluorine, chlorine, CF 3> C 3 -6- cycloalkyl, C ⁇ alkyl, and hydroxy-C M alkyl, preferably selected from d_ 3 alkyl and cyclopropyl, .auf utilizat, where two alkyl substituents to form a C. 3 7 -cycloalkyl- or C 5 . 7 -Cycloalkenyl group can be linked together.
  • the alkenylene bridge is unsubstituted or has 1, 2 or 3 substituents.
  • Preferred substituents here are d- C3 alkyl and cyclopropyl, wherein two alkyl substituents to form a C 3 - 6 cycloalkyl or C. 5 6 -Cycloalkenyl group can be linked together.
  • the bridge X is a C 3 - 6 alkynylene bridge, in particular a Q M -alkynylene bridge, which is unsubstituted or carries one, two, three or more, preferably one, two or three substituents independently selected from fluorine, chlorine, CF 3 , C 3 . 6 cycloalkyl, C ⁇ alkyl, and hydroxy-C ⁇ alkyl, preferably selected from C ⁇ -3-alkyl and cyclopropyl, said two alkyl substituents to form a C. 3 7 -Cycloalkyl group may be joined together.
  • the bridge X is preferably a -CH 2 -C ⁇ bridge, which may be substituted as indicated.
  • the alkynylene bridge is unsubstituted or has 1, 2 or 3 substituents.
  • Preferred substituents are d. 3 alkyl, and cyclopropyl, wherein two alkyl substituents to form a C 3 - 6 cycloalkyl group may be bonded together.
  • the bridge W preferably denotes a single bond or ethylene, more preferably a single bond.
  • the bridge Z is preferably a single bond or ethylene which may have one or two methyl substituents which may be linked together to form a cyclopropyl group.
  • Z is particularly preferably a single bond.
  • the group Y preferably has a meaning which is selected from the group of the bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, tetrahydronaphthyl, indolyl, dihydroindolyl, quinolinyl, dihydroquinolinyl,
  • Tetrahydroquinolinyl isoquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl,.
  • the bridges X and Z are preferably connected in para-position to the group Y.
  • Particularly preferred is a meaning of the group Y selected from the group of bivalent cyclic groups
  • Y has one of the following meanings
  • Y has one of the following meanings
  • cyclic groups may be monosubstituted or polysubstituted by one or more carbon atoms having the same or different radicals R 20 , in the In addition, if a phenyl ring is present, it may also be monosubstituted by nitro, and / or one or more NH groups may be substituted by R 21 .
  • the group Y is preferably unsubstituted or monosubstituted or disubstituted.
  • Particularly preferred substituents R 20 of the group Y are selected from the group consisting of fluorine, chlorine, bromine, cyano, nitro, C 1-4 alkyl, C 2 . 6 alkenyl, hydroxy, ⁇ -hydroxy-3 d- alkyl, C ⁇ - alkoxy, trifluoromethyl, trifluoromethoxy, C 2 - 4 alkynyl, C ⁇ - carbonyl-4 alkoxy, co- (C ⁇ - alkoxy) - C 3 -C 4 -alkoxy-carbamoylamino, amino, d. 4 alkyl-amino-, di (C 1-4 alkyl) -amino, aminocarbonyl, and di (C 1-4 alkyl) amino carbonyl.
  • R 20 of the group Y are selected from the group consisting of fluorine, chlorine, bromine, cyano, d-3 alkyl, d-3 alkoxy, C M - alkoxycarbonyl, trifluoromethyl, trifluoromethoxy, in the case of a phenyl ring may also nitro.
  • the group Y represents substituted phenylene
  • substituent L 1 has the meanings indicated, preferably F, Cl, Br, I, methyl, ethyl, ethenyl, ethynyl, CF 3 , OCH 3 , OCF 3 , -CO-CH 3 , -COOCH 3 , CN or NO 2 , or denotes H.
  • Very particularly preferred meanings of the substituent L 1 are H, F, Cl, Br, methyl, ethyl, ethenyl, acetyl or methoxy, in particular H or methyl.
  • the group A is selected from the group of bivalent cyclic groups phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, the one or more times to one or more C atoms having the same or different radicals R 20 , in the case of a phenyl ring also additionally simple with nitro, may be substituted.
  • A is one of the groups listed below
  • Substituents R 20, particularly preferred the group A are independently fluorine, chlorine, bromine, amino, CF 3, methoxy and d- C3 alkyl.
  • the groups A are unsubstituted or monosubstituted with R 20 as indicated.
  • Preferred meanings of group B according to a first preferred embodiment : .. are selected from the group consisting of phenyl, pyridyl, thienyl and furanyl.
  • the group B is phenyl.
  • the group B in the meanings given may be mono- or polysubstituted by identical or different radicals R 20 , one
  • Phenyl group additionally also be easily substituted with nitro.
  • the group is
  • substituent B is unsubstituted or monosubstituted, disubstituted or trisubstituted, in particular unsubstituted or monosubstituted or disubstituted.
  • the substituent is preferably in the para position to the group A.
  • Preferred substituents R 20 of group B are selected from the group consisting of fluorine, chlorine, bromine, cyano, nitro, C 1-4 -alkyl, hydroxy, CHF 2 , CHF 2 -O-, hydroxy-d. 3 -alkyl, -C.
  • substituents R 20 of group B are selected from the group consisting of fluorine, chlorine, bromine, cyano, CF 3 , d. 3 alkyl, C ⁇ - 4 alkoxy and trifluoromethoxy.
  • Very particularly preferred substituents R 20 of group B are selected from the group consisting of chlorine, bromine and methoxy.
  • the meaning of the group B is preferably selected from d- 6 alkyl, C 2 .e alkenyl, C. 2 6 alkynyl, C 3 . 7 -cycloalkyl, C 5 . 7- Cycloalkenyl, C 3 . 7 - cycloalkyl-d-3-alkyl, C 3 - 7 cycloalkenyl-d.3-alkyl, C 3 - 7 cycloalkyl-d-3 alkenyl, C. 3 7 - cycloalkyl-d- 3- alkynyl, wherein one or more carbon atoms in the groups mentioned above for B may be monosubstituted or polysubstituted by fluorine.
  • one or more C atoms may be substituted with R 20 .
  • the groups C 3 to C 6 alkyl, C 3 are particularly preferred. 6 - alkenyl, C 3 - 6 alkynyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclopentyl-3 C ⁇ - alkyl, cyclopentenyl d.
  • B means according to this second embodiment
  • Cyclohexenyl which is unsubstituted or has 1, 2 or 3 identical or different substituents R 20 , in particular methyl.
  • the substituent R 13 preferably has one of the meanings given for R 16 .
  • R 13 is H, d-4 alkyl, C 3rd 7 -cycloalkyl, C 3 . 7 -cycloalkyl-C 3 -alkyl-, ⁇ -hydroxy-C 2 . 3- alkyl, ⁇ - (C 1 ⁇ alkoxy) -C 2 . 3 -alkyl.
  • R 13 is H or C ⁇ - 4 alkyl.
  • the abovementioned alkyl groups may be monosubstituted by CI or monosubstituted or polysubstituted by F.
  • R 15 are H, d ⁇ -alkyl, C 3 . 7 -cycloalkyl, C 3 . 7 - cycloalkyl-C- ⁇ - 3 -alkyl-, where, as defined above, in each case one or more C atoms additionally one or more times with F and / or in each case one or two C-atoms independently additionally simply with CI or Br can be substituted. More preferably R 15 is H, CF 3 , methyl, ethyl, propyl or butyl.
  • the substituent R 6 is preferably H, d- 4- alkyl, C 3 . 7 cycloalkyl, C 3 - 7 cycloalkyl-d- 3 - alkyl, ⁇ -hydroxy-C 2 - (. C 4 alkoxy) 3 alkyl or ⁇ - -C 2 - 3 -alkyl, wherein as defined above, in each case one or more C atoms may additionally be mono- or polysubstituted with F and / or in each case one or two C atoms independently of one another may additionally be substituted simply by Cl or Br.
  • Particularly preferably R 16 is H, CF 3, d- C3 alkyl, C3-e cycloalkyl or C. 3 6 - cycloalkyl-d. 3 -alkyl. ,
  • the substituent R 7 has one of those given as preferred for R 16
  • R 17 particularly preferably has one of the meanings given for R 16 as being preferred.
  • a means or both are of the substituents R 18 and R 19 are independently hydrogen or C 4 alkyl, especially hydrogen.
  • the substituent R 20 is preferably halogen, hydroxy, cyano, d-alkyl, Q ⁇ alkenyl, C 2 . 4- alkynyl, C 3 . 7 cycloalkyl, C 3-7 cycloalkyl C ⁇ alkyl, hydroxy-C ⁇ alkyl, R 22 -d- 3 alkyl, or one of the meanings given for R 22 as being preferred, wherein, as hereinbefore defined, in each case one or more C atoms may additionally be mono- or polysubstituted with F and / or in each case one or two C atoms, in each case independently of one another, may additionally be substituted simply by Cl or Br.
  • Particularly preferred meanings of the group R 20 are halogen, hydroxy, cyano, C 1 - 4 - alkyl, C 3rd 7 -cycloalkyl, d- 3- alkylcarbonyl and C ⁇ alkoxy, where, as defined above, in each case one or more C atoms additionally one or more times with F and / or in each case one or two C atoms can additionally be substituted, independently of one another, additionally simply with CI or Br.
  • R 20 being F, Cl, Br, I, OH, cyano, methyl, difluoromethyl, trifluoromethyl, ethyl, n-propyl, isopropyl, acetyl, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy or isobutyl. propoxy.
  • the substituent R 22 is preferably d. 4 -alkoxy, d ⁇ -alkylthio, carboxy, d. Alkylcarbonyl, d- alkoxycarbonyl, aminocarbonyl, d- 4 alkylaminocarbonyl, di- (d.
  • R 22 are C w - alkoxy, C- ,. 3 alkylcarbonyl, amino, d- 4 alkylamino, di- (C, 4 alkyl) -amino, wherein one or more H atoms may be replaced by fluorine.
  • R 21 are d ⁇ -alkyl, d. 4 alkylcarbonyl, d- 4 - alkylsulfonyl, -S0 2 -NH 2, -S0 2 -NH-d-3 alkyl, -S ⁇ 2 -N (d- C3 alkyl) 2 and cyclo-C. 3 6 -alkyleniminosulphonyl-, where, as defined above, in each case one or more C atoms additionally mono- or polysubstituted with F and / or in each case one or two C atoms, independently of one another, can additionally be substituted simply by Cl or Br. Most particularly preferably R 21 C ⁇ - 4 alkyl or CF 3.
  • Cy is preferably a C 3 . 7 cycloalkyl, in particular a C 3 - 6 cycloalkyl group, a C 5-7 cycloalkenyl group, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl,
  • Very particularly preferred meanings of the group Cy are C 3 . 6 -cycloalkyl, pyrrolidinyl and piperidinyl, which may be substituted as indicated.
  • aryl is preferably phenyl or naphthyl, in particular phenyl.
  • heteroaryl preferably includes pyridyl, indolyl, quinolinyl and benzoxazolyl.
  • Those compounds according to the invention are preferred in which one or more of the groups, radicals, substituents and / or indices has one of the meanings given above as being preferred.
  • Particularly preferred compounds according to the invention can be prepared with a general formula IIIa, IIb, IIc, IId, very particularly preferably IIa and IIb,
  • R 3 1, R, X and Z have one of the meanings mentioned above and
  • L ⁇ L 2 , L 3 independently of one another have one of the meanings given for R 20 , and
  • n independently of one another the values 0, 1 or 2, p also the value 3.
  • L 1 is fluorine, chlorine, bromine, cyano, d-3 alkyl, d-3 alkoxy, C M alkoxycarbonyl, trifluoromethyl, Trifluo ⁇ methoxy, nitro,
  • n 0 or 1
  • L 2 is fluorine, chlorine, bromine, CN, amino, CF 3 , methoxy and d. 3- alkyl,
  • L 3 independently selected from the meanings fluorine, chlorine, bromine, cyano, nitro, d-alkyl, hydroxy, ⁇ -hydroxy-d- 3- alkyl, C ⁇ alkoxy, trifluoromethyl, trifluoromethoxy, C 2 . 4 alkynyl, carboxy, d ⁇ alkoxycarbonyl, ⁇ - (C ⁇ - 4 alkoxy) -d- 3- alkyl-, d. Alkoxy-carbonylamino, amino, C ⁇ alkyl amino, di- (d. 4-alkyl) -amino, cyclo-C3.
  • p 0, 1, 2 or 3, in particular 1 or 2.
  • R 1 , R 2 are joined together and, together with the N-atom to which they are attached, form a heterocyclic group selected from pyrrolidine, piperidine, 8-azabicyclo [3.2.1] octane, piperazine, in which the free imine function is substituted by R 13 , and morpholine, where one or more H atoms may be replaced by identical or different R 4 radicals, and wherein the previously defined heterocyclic group is linked via a single bond to a carbo- or heterocyclic group Cy may be substituted, wherein Cy is selected from the group consisting of C 3 7 cycloalkyl, and cyclo-C 3 -.
  • R 20 may where R 20 is as previously defined and is preferably selected from fluoro, CF 3 , D 3 alkyl, hydroxy-D 3 -alkyl and hydroxy, and
  • R 14 is selected from F, Cl, Br, d-4 alkyl, hydroxy, hydroxy-C ⁇ - 3 alkyl, C 14 alkoxy, ⁇ - (C ⁇ - 4 alkoxy) C 1-3 alkyl , Amino-d- 3- alkyl, C ⁇ - 4- alkyl-amino-C 1 - 3 -alkyl-, C 3 . 7 - cycloalkyl-amino-d-3 alkyl, N- (C 3 - 7 cycloalkyl) -N- (C 1 - 4 alkyl) amino-C 1 - 3 alkyl, di (C 1 4- alkyl) -amino-C ⁇ .
  • X is a C 2 . 4- alkylene bridge, the 1, 2 or 3 substituents independently selected from d. Having 3 -alkyl and cyclopropyl, wherein two alkyl substituents to form a C 3 - 6 cycloalkyl group may be bonded together, or a C 2 ⁇ alkyleneoxy bridge containing 1, 2 or 3 substituents independently each other selected from d- 3 alkyl and cyclopropyl, wherein two alkyl substituents may be joined together to form a C 3 -6-cycloalkyl group, or a C 2 - 3 -alkyleneimino bridge, wherein the imino group by a Group may be substituted, and in which the alkylene moiety of 1, 2 or 3 substituents independently selected from C- ⁇ - C3 alkyl and cyclopropyl, wherein two alkyl groups to form a C 3 - 6 - cycloalkyl group, or, if a Alkyl group is
  • 4- alkenylene or Cs ⁇ alkynylene bridge which is unsubstituted or 1, 2 or 3 substituents independently selected from d. 3 alkyl and cyclopropyl, wherein two alkyl substituents to form a C 3 . 6 - cycloalkyl or C 5 - 6 cycloalkenyl group may be joined together.
  • halogen denotes an atom selected from the group consisting of F, Cl, Br and I, in particular F, Cl and Br.
  • C ⁇ - n -alkyl where n has a value of 3 to 8 has, means a saturated, branched or unbranched hydrocarbon group with 1 to n C atoms.
  • examples of such groups include methyl, ethyl, n-propyl, iso -propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-hexyl, etc.
  • C ⁇ . n -Alkylen where n can have a value of 1 to 8, means a saturated, branched or unbranched hydrocarbon bridge having 1 to n carbon atoms.
  • groups include methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), 1-methyl-ethylene (-CH (CH 3 ) -CH 2 -), 1,1-dimethyl-ethylene (-C (CH 3 ) 2 -CH 2 -), n -prop-1, 3-ylene (-CH 2 -CH 2 -CH 2 -), 1-methylprop-1, 3-ylene (-CH (CH 3 ) -CH 2 -CH 2 -), 2-methylprop-1, 3-ylene (-CH 2 -CH (CH 3 ) -CH 2 -), etc., as well as the corresponding mirror-image forms.
  • groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, etc.
  • C 2 . n- alkynyl wherein n has a value of 3 to 6, denotes a branched or unbranched hydrocarbon group having 2 to n C atoms and a C ⁇ C triple bond.
  • groups include ethynyl, 1-propynyl, 2-propynyl, isopropynyl, 1-butynyl, 2-butynyl, 3-butynyl, 2-methyl-1-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-2-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, etc.
  • Ci n alkoxy refers to a C- ⁇ - n-alkyl-O group wherein n Ci- alkyl is as defined above.
  • groups include methoxy, ethoxy, n-propoxy, iso -propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n- Hexoxy, iso-hexoxy etc.
  • d- n- alkylthio denotes a C n- alkyl-S group, in which C n-n- alkyl is as defined above.
  • groups include methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, neo-pentylthio, tert-pentylthio, n-butylthio Hexylthio, iso-hexylthio, etc.
  • groups include methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, iso -propylcarbonyl, n-butylcarbonyl, iso-butylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl, n-butyl Hexylcarbonyl, iso-hexylcarbonyl, etc.
  • n- Cycloalkyl denotes a saturated mono-, bi-, tri- or spirocarbocyclic, preferably monocarbocyclic group having 3 to n C atoms.
  • groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, Cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo [3.2.1.] Octyl, spiro [4.5] decyl, norpinyl, norbornyl, norcaryl, adamantyl, etc.
  • C 5 . n -Cycloalkenyl denotes a monounsaturated mono-, bi-, tri- or spirocarbocyclic, preferably monocarbocyclic group having 5 to n carbon atoms.
  • Examples of such groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc.
  • aryl refers to a carbocyclic aromatic ring system such as phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, indenyl, pentalenyl, azulenyl, biphenylenyl, etc.
  • a particularly preferred meaning of "aryl” is phenyl.
  • cyclo-C 3 . 6 -alkyleneimino- refers to a 4- to 7-membered ring having from 3 to 6 methylene units and an imino group, the bond to the rest of the molecule being via the imino group.
  • cyclo-C 3 - 6 -alkylenimino-carbonyl denotes a previously defined cyclo-C 3 . 6 - Alkylenimino ring which is connected via the imino group with a carbonyl group.
  • heteroaryl used in this application denotes a heterocyclic aromatic ring system which, in addition to at least one C atom, has one or more
  • Heteroatoms selected from N, O and / or S includes.
  • Examples of such groups are furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,3-triazolyl, 1, 3,5-triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1, 2, 3-triazinyl, 1, 2,4-triazinyl, 1, 3,5-triazinyl, 1, 2,3-oxadiazolyl, 1, 2,4-oxadiazolyl, 1, 2,5-oxadiazolyl, 1, 3,4- Oxadiazolyl,, 2,3-thiadiazolyl, 1, 2,4-thiadiazolyl, 1, 2,5-thiadiazolyl, 3,4-thiadiazolyl, tetrazolyl, thiadiazinyl, indo
  • heteroaryl also encompasses the partially hydrogenated heterocyclic aromatic ring systems, in particular the ring systems listed above.
  • partially hydrogenated Heterocycles are 2,3-dihydrobenzofuranyl, pyrolinyl, pyrazolinyl, indolinyl, oxazolidinyl, oxazolinyl, oxazepinyl, etc.
  • Particularly preferred heteroaryl means a heteroaromatic mono- or bicyclic ring system.
  • unsaturated for example in “unsaturated carbocyclic group” or “unsaturated heterocyclic group”, as used in particular in the definition of the group Cy, in addition to the mono- or polyunsaturated groups also includes the corresponding fully unsaturated groups, but especially mono- and diunsaturated groups.
  • this substituent may be attached to any free position of the cyclic group bearing an H atom.
  • the H atom of an existing carboxy group or an H atom bound to an N atom (imino or amino group) can each be replaced by a residue which can be split off in vivo.
  • Under a cleavable by a N-atom in vivo radical is understood to mean, for example, a hydroxy group, an acyl group such as the benzoyl or pyridinoyl group, or a d ..
  • alkanoyl group such as formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl group, a C 16 alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, part.
  • R f is a hydrogen atom, a C 3 -alkyl, C 5 . 7 -cycloalkyl or phenyl group and
  • R g is a hydrogen atom, a C 3 alkyl or R ⁇ CO-O- (R f CR g) -O- group, in which R g to R e are defined as mentioned above, represent
  • the phthalimido group is contemplated, wherein the above-mentioned ester groups can also be used as in vivo into a carboxy group convertible group.
  • radicals and substituents described above may be mono- or polysubstituted by fluorine in the manner described.
  • Preferred fluorinated alkyl radicals are fluoromethyl, difluoromethyl and trifluoromethyl.
  • Preferred fluorinated alkoxy radicals are fluoromethoxy, difluoromethoxy and trifluoromethoxy.
  • Preferred fluorinated alkylsulfinyl and alkylsulfonyl groups are trifluoromethylsulfinyl and trifluoromethylsulfonyl.
  • the compounds of the general formula I according to the invention may have acid groups, mainly carboxyl groups, and / or basic groups, e.g. Amino functions.
  • Compounds of the general formula I can therefore be used as internal salts, as salts with pharmaceutically usable inorganic acids such as hydrochloric acid,
  • Sulfuric acid, phosphoric acid, sulfonic acid or organic acids such as Maleic acid, fumaric acid, citric acid, tartaric acid or acetic acid
  • pharmaceutically usable bases such as alkali metal or alkaline earth metal hydroxides or carbonates, zinc or ammonium hydroxides or organic amines such as diethylamine, triethylamine, triethanolamine and the like.
  • the compounds according to the invention can be obtained using synthesis methods known in principle.
  • the compounds are preferably obtained according to the preparation process according to the invention explained in more detail below.
  • the halogen compound A.1 is reacted with the alkyne compound A.2 in a molar ratio of about 1.5: 1 to 1: 1.5 in a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper (I). iodide reacted in a suitable solvent.
  • a preferred amount of copper (I) iodide in this case is in the range from 1 to 15 mol%, in particular from 5 to 10 mol%, based on the educt A.1.
  • Suitable palladium catalysts are Pd (PPh 3 ) 4 , Pd 2 (dba) 3 , Pd (OAc) 2 , Pd (PPh 3 ) 2 Cl 2 , Pd (CH 3 CN) 2 Cl 2 , Pd (dppf) Cl 2 .
  • the palladium catalyst is preferably used in an amount of from 1 to 15 mol%, in particular from 5 to 10 mol%, based on the educt A.1.
  • Suitable bases are in particular amines, such as triethylamine or
  • Ethyldiisopropylamine as well as Cs 2 CO 3 .
  • the base is preferably used in at least equimolar amount based on the educt A.1, in excess or as a solvent.
  • suitable solvents are dimethylformamide or ethers such as tetrahydrofuran, including mixtures thereof.
  • the reaction is carried out in a period of about 2 to 24 hours in a temperature range of about 20 to 90 ° C.
  • the resulting alkyne compound A.3 is reacted directly or after prior purification with methanesulfonyl chloride to methanesulfonate derivative A.4.
  • the reaction conditions to be observed are known to those skilled in the art.
  • Advantageous solvents are halogenated hydrocarbons, such as dichloromethane. Suitable reaction temperatures are usually in a range of 0 to 30 ° C.
  • the reaction solution containing the methanesulfonate derivative A4 or the purified methanesulfonate derivative A.4, dissolved in a suitable solvent, is reacted with an amine H-NR 1 R 2 to give the final product A.5 and then optionally purified.
  • Has the amine H-NR R 2 is a further primary or secondary amine function, these advantageous is previously provided with a protecting group known from the literature after the reaction using procedures can be split off again.
  • the product thus obtained can be converted into the salt form, for example, by reaction with a corresponding acid.
  • a preferred molar ratio of the derivative A.4 to the amine compound is in the range from 1.5: 1 to 1: 1.5.
  • Suitable solvents are dimethylformamide or ethers such as tetrahydrofuran, including mixtures thereof.
  • the reaction to the product A.5 is advantageously carried out in a temperature range of about 20 to 90 ° C.
  • the halogen compound C.1 is reacted with the alkyne compound C.2 in a molar ratio of about 1.5: 1 to 1: 1.5 under a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper ( l) iodide reacted in a suitable solvent directly to the product C.3.
  • Reaction Scheme D An alternative synthesis is shown in Reaction Scheme D. Accordingly, the halogen compound D.2 with the alkyne compound D.1 in a molar ratio of about 1, 5: 1 to 1: 1.5 under a protective gas atmosphere in the presence of a suitable palladium catalyst, a suitable base and copper (I) iodide in reacted directly to the product D.3 a suitable solvent.
  • a suitable palladium catalyst a suitable base and copper (I) iodide
  • Hai in the compounds A.1, B.2, C.1 and D.2 is bromine, it is advantageous to previously convert this into the corresponding iodine compound.
  • a particularly advantageous process is the aryl-Finkelstein reaction (Klapars, Artis, Buchwald, Stephen L. Copper-Catalyzed Halogen Exchange in Aryl Halides: An Aromatic Finkelstein Reaction, Journal of the American Chemical Society (2002), 124 (50 ), 14844-14845).
  • the halogen compound A.1, B.2, C.1 or D.2 can be reacted with sodium iodide in the presence of ⁇ /, ⁇ / '- dimethylethylenediamine and copper (I) iodide in a suitable solvent to give the corresponding iodine compound become.
  • Halogen compound to sodium iodide is 1: 1.8 to 1: 2.3.
  • W, '-Dimethyl-ethylenediamine is advantageously used in a molar ratio of 10 to 30 mol% based on the halogen compound A.1, B.2, C.1 or D.2.
  • Preferred amounts of copper (I) iodide are in the range of 5 to 20 mol% based on the halogen compound A.1, B.2, C.1 or D.2.
  • a hiebei suitable solvent is, for example, 1, 4-dioxane. suitable
  • Reaction temperatures are in the range of about 20 to 110 ° C. The reaction is essentially complete after 2 to 72 hours.
  • stereoisomeric compounds of the formula (I) can be separated by customary methods.
  • the separation of the respective diastereomers succeeds due to their different physicochemical properties, eg by fractional crystallization from suitable solvents, by high pressure liquid or column chromatography using chiral or preferably achiral stationary phases.
  • racemates covered by the general formula (I) succeeds, for example, by HPLC on suitable chiral stationary phases (eg Chiral AGP, Chiralpak AD). Racemates which contain a basic or acidic function can also be resolved via the diastereomeric, optically active salts which, when reacted with an optically active acid, for example (+) - or (-) - tartaric acid, (+) - or (-) ) -Diacetyltartaric acid, (+) - or (-) - monomethyl tartrate or (+) - camphorsulfonic acid, or an optically active base, for example with (R) - (+) - 1-phenylethylamine, (S) - (-) - 1-phenylethylamine or (S) -Brucin arise.
  • an optically active acid for example (+) - or (-) - tartaric acid, (+) - or (-) ) -Diacetyltartaric acid, (+) - or (-
  • the racemate of a compound of the general formula (I) is reacted with one of the above-mentioned optically active acids or bases in an equimolar amount in a solvent and the resulting crystalline, diastereomeric, optically active salts taking advantage of their different solubility separated.
  • This reaction can be carried out in any kind of solvents as long as they have a sufficient difference in the solubility of the salts.
  • methanol, ethanol or mixtures thereof, for example in the volume ratio 50:50, are used.
  • each of the optically active salts is dissolved in water, carefully neutralized with a base such as sodium carbonate or potassium carbonate, or with a suitable acid, for example, with dilute hydrochloric acid or aqueous methanesulfonic acid, thereby giving the corresponding free compound in the (+) - or ( -) - Form received.
  • a base such as sodium carbonate or potassium carbonate
  • a suitable acid for example, with dilute hydrochloric acid or aqueous methanesulfonic acid
  • the compounds of the formula (I) can be converted into their salts, in particular for the pharmaceutical application, into their physiologically and pharmacologically tolerable salts. These salts may be present on the one hand as physiologically and pharmacologically acceptable acid addition salts of the compounds of the formula (I) with inorganic or organic acids.
  • the compound of formula (I) may be reacted with inorganic bases are also converted into physiologically and pharmacologically acceptable salts with alkali or alkaline earth metal cations as the counterion.
  • Hydrochloric acid hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid come into consideration for the preparation of the acid addition salts. Furthermore, mixtures of the abovementioned acids can be used.
  • the alkali metal and alkaline earth metal salts of the compound of the formula (I) with acidically bonded hydrogen preference is given to the alkali metal and alkaline earth metal hydroxides and hydrides, the hydroxides and hydrides of the alkali metals, in particular of sodium and potassium, preferably sodium and potassium hydroxide are particularly preferred.
  • the compounds according to the present invention include the physiologically acceptable salts, have an activity as antagonists of the MCH receptor, in particular of the MCH-1 receptor, and show good affinities in MCH receptor.
  • the compounds of the invention are advantageously useful as pharmaceutical agents for the prophylaxis and / or treatment of phenomena and / or diseases caused by MCH or in another causal relationship with MCH.
  • the compounds according to the invention have low toxicity, good oral absorbability and intracerebral transitivity, in particular cerebral activity.
  • MCH antagonists which have at least one compound of the invention, especially in mammals, such as rats, mice, guinea pigs, rabbits, dogs, cats, sheep, horses, pigs, cattle, monkeys and humans, for the treatment and / or prophylaxis of Phenomena and / or diseases caused by MCH or in another causal relationship with MCH.
  • Diseases caused by MCH or otherwise causally related to MCH include, in particular, metabolic disorders, such as obesity, and eating disorders, such as bulimia, including bulimia nervosa.
  • the indication obesity includes especially exogenous obesity, hyperinsulinar obesity, hyperplastic obesity, hyperphyseal obesity, hypoplasmic obesity, hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile obesity, upper body obesity, alimentary obesity, hypogonadal obesity, central obesity.
  • cachexia, anorexia and hyperphagia are to be mentioned in this indication environment.
  • compounds of the invention may be useful in reducing hunger, curbing appetite, controlling eating behavior, and / or inducing satiety.
  • diseases caused by MCH or otherwise causally related to MCH may include hyperlipidemia, cellulitis, fat accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, mood disorders, depression, anxiety, sleep disorders, reproductive disorders, sexual disorders , Memory disorders, epilepsy, forms of dementia and hormone disorder include.
  • Compounds of the invention are also useful as agents for the prophylaxis and / or treatment of other diseases and / or disorders, especially those associated with obesity, such as diabetes, diabetes mellitus, especially type II diabetes, hyperglycemia, especially chronic hyperglycemia, diabetic complications, including diabetic Retinopathy, diabetic neuropathy, diabetic nephropathy, etc., insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, especially arteriosclerosis and hypertension, arthritis and gonitis.
  • diseases and / or disorders especially those associated with obesity, such as diabetes, diabetes mellitus, especially type II diabetes, hyperglycemia, especially chronic hyperglycemia, diabetic complications, including diabetic Retinopathy, diabetic neuropathy, diabetic nephropathy, etc., insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, especially arteriosclerosis and hypertension, arthritis and gonitis.
  • MCH antagonists and formulations according to the invention can advantageously be used in combination with an alimentary therapy, such as, for example, an alimentary diabetes therapy, and exercise.
  • Another area of indication for which the compounds of the invention are advantageously useful is the prophylaxis and / or treatment of voiding disorders such as urinary incontinence, overactive bladder, urinary urgency, nocturia, enuresis, with overactive bladder and urinary urgency with or without benign prostatic hyperplasia Need to be connected.
  • the compounds of the invention are potentially useful to prevent and / or treat dependencies such as alcohol and / or nicotine addiction and / or withdrawal symptoms, such as weight gain in nicotine withdrawal from smokers.
  • dependency is here generally an irresistible urge to take an addictive substance and / or perform certain acts, in particular either to achieve a feeling of well-being or to eliminate discomfort understood.
  • an addictive dependency is understood here as "dependency”.
  • “Withdrawal symptoms” are generally understood here to be symptoms that occur or may occur in the withdrawal of addictive substances in patients dependent on one or more such addictive substances.
  • the compounds of the present invention are potentially useful as agents to reduce or stop the consumption of tobacco, to treat or prevent nicotine dependence and / or to treat or prevent nicotine withdrawal symptoms, reduce cravings for tobacco and / or nicotine and generally Remedy for smoking.
  • the compounds of the present invention may be useful to prevent or at least reduce the weight gain associated with nicotine withdrawal from smokers.
  • the substances can furthermore be suitable as active ingredients which prevent or at least reduce the craving for and / or relapse into dependence on addictive substances.
  • Addictive substances are understood to mean in particular but not exclusively psycho-motor active substances, such as narcotics or intoxicants, in particular alcohol, nicotine, cocaine, amphetamine, opiates, benzodiazepines and barbiturates.
  • the dosage required to achieve a corresponding effect is expediently from 0.001 to 30 mg / kg given intravenously or subcutaneously
  • Body weight preferably 0.01 to 5 mg / kg body weight, and by oral, nasal or inhalative administration 0.01 to 50 mg / kg body weight, preferably 0.1 to 30 mg / kg body weight, once to three times daily.
  • the compounds of general formula I according to the invention cane sugar, microcrystalline cellulose, Magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixtures in conventional pharmaceutical preparations such as tablets, dragees, capsules, wafers, powders, granules, solutions, emulsions, syrups, inhalation aerosols, ointments, suppositories incorporate.
  • inert conventional carriers and / or diluents for example with corn starch, lactose
  • inert conventional carriers and / or diluents for example with corn starch, lactose
  • inert conventional carriers and / or diluents for example with corn starch,
  • compositions comprising at least one alkyne compound according to the invention and / or a salt according to the invention in addition to optionally one or more physiologically acceptable excipients.
  • Such compositions may, for example, also be foodstuffs which may be solid or liquid, in which the compound according to the invention is incorporated.
  • suitable further active substances are, in particular, those which, for example, enhance the therapeutic effectiveness of an MCH antagonist according to the invention with regard to one of the indicated indications and / or which allow a reduction in the dosage of an MCH antagonist according to the invention.
  • one or more other active substances are selected from the group consisting of active ingredients for the treatment of diabetes, drugs for the treatment of diabetic complications, drugs for the treatment of obesity, preferably other than MCH antagonists, - agents for the treatment of hypertension, drugs for the treatment of hyperlipidemia including atherosclerosis, drugs for the treatment of dyslipidemia, including arteriosclerosis, drugs for the treatment of arthritis, drugs for the treatment of anxiety, - drugs for the treatment of depression.
  • Examples of drugs for the treatment of diabetes are insulin sensitizers, insulin secretagogues, biguanides, insulins, ⁇ -glucosidase inhibitors, ⁇ 3 adreno receptor agonists.
  • Insulin sensitizers include glitazones, especially pioglitazones and its salts (preferably hydrochlorides), troglitazones, rosiglitazones and its salts (preferably Maleate), JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929.
  • glitazones especially pioglitazones and its salts (preferably hydrochlorides), troglitazones, rosiglitazones and its salts (preferably Maleate), JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-1258, KRP-297, R-119702, GW-1929.
  • Insulin secretion enhancers include sulfonylureas such as tolbutamide, chlorpropamide, tolzamide, acetohexamide, glyclopyramide and its
  • Ammonium salts glibenclamide, gliclazides, glimepirids.
  • Further examples of insulin secretion accelerators are repaglinide, nateglinide, mitiglinide (KAD-1229), JTT-608.
  • Biguanides include metformin, buformin, phenformin.
  • Insulins include insulins derived from animals, particularly cattle or swine, semi-synthetic human insulins enzymatically synthesized from animal-derived insulin, human insulin obtained by genetic engineering, for example from Escherichia coli or yeasts. Further, as insulin insulin zinc
  • protamine insulin zinc available from zinc chloride, protamine sulfate and insulin.
  • insulin can be obtained from insulin fragments or derivatives (e.g., INS-1, etc.).
  • Insulin may also include different types, for example with respect to
  • ⁇ -glucosidase inhibitors include acarbose, voglibose, miglitol, emiglitate.
  • ⁇ 3 adreno receptor agonists include AJ-9677, BMS-196085, SB-226552, AZ40140.
  • Agents for the treatment of diabetic complications include, for example, aldose reductase inhibitors, glycation inhibitors, protein kinase C inhibitors, DPPIV blockers, GLP-1 or GLP-1 analogs, SGLT-2 inhibitors.
  • Aldose reductase inhibitors are, for example, Tolrestat, Epalrestat, Imirestat, Zenarestat, SNK-860, Zopolrestat, ARI-50 ⁇ , AS-3201.
  • Protein kinase C inhibitors are, for example, NGF, LY-333531.
  • DPPIV blockers are for example LAF237 (Novartis), MK431 (Merck) as well as 815541, 823093 and 825964 (all GlaxoSmithkline).
  • GLP-1 analogs are for example Liraglutide (NN2211) (NovoNordisk), CJC1131 (Conjuchem), Exenatide (Amlyin).
  • SGLT-2 inhibitors are AVE-2268 (Aventis) and T-1095 (Tanabe, Johnson & Johnson).
  • Agents for the treatment of obesity include lipase inhibitors and anorectics.
  • a preferred example of a lipase inhibitor is orlistat.
  • preferred anorectic agents are phentermine, mazindol, dexfenfluramine, fluoxetine, sibutramine, baiamine, (S) -sibutramine, SR-141716, NGD-95-1.
  • the group of active substances of the anti- Obesity drugs are also counted as anorexics, with the ß 3 agonists, thyromimetic agents and NPY antagonists being emphasized.
  • the scope of the substances considered to be preferred as anti-obesity or anorectic agents is exemplified by the following list: phenylpropanolamine, ephedrine, pseudoephedrine, phentermine, a cholecystokinin-A (hereinafter referred to as CCK-A) agonist, a monoamine reuptake ( reuptake) inhibitor (such as sibutramine), a sympathomimetic agent, a serotonergic agent (such as dexfenfluramine, fenfluramine, or a 5-HT2C agonist such as BVT.933 or APD356, or duloxetine), a dopamine agonist (such as brorocropylpyridine or Pr
  • anorectives include bombesin agonists, dehydroepiandrosterone or its analogs, glucocorticoid receptor agonists and antagonists, orexin receptor antagonists, urocortin binding protein antagonists, agonists of the glucogon-like peptide-1 receptor, such as exendin, AC 2993, CJC-1131, ZP10 or GRT0203Y, DPPIV Inhibitors and ciliary neurotrophic factors, such as axokines.
  • therapies should be mentioned in this context, which lead to weight loss by increasing the fatty acid oxidation in peripheral tissue, such as inhibitors of acetyl-CoA carboxylase.
  • Agents for the treatment of hypertension include inhibitors of angiotensin converting enzyme, calcium antagonists, potassium channel openers, angiotensin II antagonists.
  • Inhibitors of the angiotensin converting enzyme include captopril, enalapril, alacepril, delapril (hydrochloride), lisinopril, imidapril, benazepril, cilazapril, temocapril, trandolapril, manidipine (hydrochloride).
  • Examples of calcium antagonists are nifedipine, amlodipine, efonidipine, nicardipine.
  • Potassium channel openers include Levcromakalim, L-27152, AL0671, NIP-121.
  • Angiotensin II antagonists include telmisartan, losartan, candesartan cilexetil, valsartan, irbesartan, CS-866, E4177.
  • Agents for the treatment of hyperlipidemia include arteriosclerosis, include HMG-CoA reductase inhibitors, fibrate compounds.
  • Inhibitors include pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, lipantil, cerivastatin, itavastatin, ZD-4522 and their salts.
  • Fibrate compounds include bezafibrates, clinofibrates, clofibrates, simfibrates.
  • Agents for the treatment of dyslipidemia, including arteriosclerosis include e.g. Drugs that increase HDL spotting, such as Nicotinic acid and its derivatives or preparations, such as Niaspan, and agonists of the nicotinic acid receptor.
  • Drugs that increase HDL spotting such as Nicotinic acid and its derivatives or preparations, such as Niaspan, and agonists of the nicotinic acid receptor.
  • NSAIDs non-steroidal antiinflammatory drugs
  • COX2 inhibitors such as meloxicam or ibuprofen.
  • Agents for the treatment of anxiety include chlordiazepoxides, diazepam, oxazolam, medazepam, cloxazolam, bromazepam, lorazepam, alprazolam, fludiazepam.
  • Agents for the treatment of depression include fluoxetine, fluvoxamine, imipramine, paroxetine, sertraline.
  • the dose for these active substances is expediently 1/5 of the usually recommended lowest dosage up to 1/1 of the normally recommended dosage.
  • the invention also relates to the use of at least one alkyne compound according to the invention and / or a salt according to the invention for influencing the eating behavior of a mammal.
  • This use is based in particular on the fact that compounds according to the invention may be suitable for reducing hunger, curbing appetite, controlling eating behavior and / or inducing satiety.
  • the eating behavior is favorably influenced so that the food intake is reduced. Therefore, find the inventive Compounds beneficial application for reducing body weight.
  • Another use of the invention is to prevent an increase in body weight, for example, in people who have previously taken weight-loss measures and are subsequently interested in maintaining the reduced body weight. In accordance with this embodiment, it is preferably a non-therapeutic use.
  • Such a non-therapeutic use may be a cosmetic application, for example, for altering the appearance or an application for improving the general condition.
  • the compounds according to the invention are preferably used for mammals, in particular humans, non- ⁇ . used therapeutically that have no diagnosed disorders of eating behavior, no diagnosed obesity, bulimia, diabetes and / or no diagnosed voiding disorders, especially urinary incontinence.
  • the compounds of the invention are suitable for non-therapeutic use in humans whose body mass index (BMI), defined as the kilogram of body weight divided by height (in meters) squared, is below the value of 30, in particular below 25, lies.
  • BMI body mass index
  • Chamber saturation determined.
  • the R r values determined under the name Alox are determined using TLC plates alumina 60 F254 (E. Merck, Darmstadt, Article No. 1.05713) without chamber saturation.
  • silica gel from Millipore (MATREX TM, 35-70 my) or Alox E. Merck, Darmstadt, aluminum oxide 90 standardized, 63-200 ⁇ m, article no: 1.01097.9050
  • the ratios indicated for the flow agents relate to volume units of the respective solvents.
  • the volume units indicated for NH 3 solutions refer to a concentrated solution of NH 3 in water.
  • the acid, base and salt solutions used in the workups of the reaction solutions are aqueous systems of the stated concentrations.
  • the indicated HPLC data are measured under the following parameters: Analytical columns: Zorbax column (Agilent Technologies), SB (stable bond) C18; 3.5 ⁇ m; 4.6 x 75 mm; Column temperature: 30 ° C; Flow: 0.8 mL / min; Injection volume: 5 ⁇ L; 254 nm detection (Methods A, B and F) Analytical columns: Zorbax column (Agilent Technologies), Bonus RP CJ4; 3-5 ⁇ m; 4.6 x 75 mm; Column temperature: 30 ° C; Flow: 0.8 mL / min; Injection volume: 5 ⁇ L; Detection at 254 nm (methods C, D and E)
  • Preparative column Zorbax column (Agilent Technologies), SB (stable bond) - C18; 3.5 ⁇ m; 30 x 100 mm; Column temperature: room temperature; Flow: 30 mL / min; Detection at 254 nm.
  • Preparative HPLC purifications generally use the same gradients used in the collection of analytical HPLC data. The collection of products is mass-controlled, the product-containing fractions are combined and freeze-dried. Chromatographic purifications with Hyperprep from Thermohypersil, Darmstadt Stationary phase HS C18; 8 ⁇ M (eluent A (water + 0.15% HCOOH), eluant B (methanol)).
  • a suitable palladium catalyst eg Pd (PPh 3 ) 4 (5 mol%) is successively added to a solution of the aryl or heteroaryl iodide or bromide (1.0 eq.) And the alkyne (1.05 eq.) In THF or DMF.
  • Pd (PPh 3 ) 2 Cl 2 5 mol%), Pd (CH 3 CN) Cl 2 (5 mol%) or Pd (dppf) Cl 2 (5 or 10 mol%)
  • a suitable base eg Cesium carbonate (1.5 eq.) Or triethylamine (1.5 eq.)
  • Cul 5 or 10 mol%).
  • the reaction solution is stirred for 2-24 h at RT to 90 ° C, filtered and the solvent i.vac. away. Further purification is carried out by column chromatography or by purification by means of HPLC-MS.
  • A1a 4- (2,2,2-trifluoro-1-hydroxy-ethyl) -piperidine-1-carboxylic acid benzyl ester To a solution of 7.42 g (30.0 mmol) of benzyl 4-formyl-piperidine-1-carboxylate in 120 mL THF 0.46 g (3.0 mmol) of cesium fluoride are added, the mixture cooled to -10 ° C, slowly added 18.0 mL (36.0 mmol) of trimethyl-trifluoromethyl-silane (2.5 M in THF), 1.5 h at -10 ° C and 1.5 h stirred at RT. 120 mL 1 N HCl are added dropwise and stirred for 1 h.
  • A2a 1- (1-Benzylpyrrolidin-3-yl) -4-methyl-piperidine To a solution of 6.0 mL (50.7 mmol) 4-methylpiperidine and 8.14 mL (50.7 mmol) 1-benzylpyrrolidin-3-one in 200 mL of THF are added to 13.0 g (61.5 mmol) of sodium triacetoxyborohydride and 2.37 mL (41.44 mmol) of AcOH and the reaction solution is stirred at RT overnight. Saturated NaHCO 3 solution is added to the reaction mixture, extracted exhaustively with EtOAc and the combined organic phases are dried over MgSO 4 .
  • MeOH is mixed with 0.6 g of 10% Pd / C and hydrogenated at RT and 4 bar until the theoretical uptake of hydrogen (4 h).
  • the catalyst is filtered off, washed with MeOH and the solvent i.vac. concentrated.
  • Analog 4.1f is prepared from 60 mg (0.13 mmol) of methanesulfonic acid 3- ⁇ 4- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -phenyl ⁇ -cyclopentyl ester and 45 mg (0.39 mmol) of 4-methyl -piperidin-4-ol obtained the product.
  • Analog 4.1f is prepared from 60 mg (0.13 mmol) of methanesulfonic acid 3- ⁇ 4- [5- (4-chloro-phenyl) -pyridine.
  • Analogous 4.1f is prepared from 60 mg (0.13 mmol) of methanesulfonic acid 3- ⁇ 4- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -phenyl ⁇ -cyclopentyl ester and 71 ⁇ L (0.65 mmol) of S- ( +) - 2-hydroxymethylpyrrolidine the product obtained.
  • Analog 5.1e is prepared from 82 mg (0.18 mmol) methanesulfonic acid 1- ⁇ 4- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -phenyl ⁇ -pyrrolidin-3-yl-ester and 91 mg ( 0.90 mmol) of (S) - (+) - 2-hydroxymethylpyrrolidine the product.
  • Analog 6.1e is prepared from 80 mg (0.14 mmol, 80% content) of (R) -methanesulfonic acid 1- ⁇ 5- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidin-3-yl-ester and 0.17 mL (1.41 mmol) 4-methylpiperidine.
  • Analog 6.1e is prepared from 100 mg (0.18 mmol, 80% content) of (R) -methanesulfonic acid 1- ⁇ 5- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidin-3-yl-ester and 116 mg (0.88 mmol) piperidine-4-carboxamide obtained the product.
  • Analog 6.1e is prepared from 100 mg (0.18 mmol, 80% content) of (R) -methanesulfonic acid 1- ⁇ 5- [5- (4-chloro-phenyl) -pyridine-72-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidine 3-yl ester and 100 mg (0.88 mmol) of 3,5-dimethylpiperidine, the product.
  • Analog 6.1e is prepared from 100 mg (0.18 mmol, 80% content) of (R) -methanesulfonic acid 1- ⁇ 5- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidin-3-yl-ester and 89 mg (0.88 mmol) of (S) - (+) - prolinol the product obtained.
  • Analog 6.1e is prepared from 100 mg (0.18 mmol, 80% content) of (R) -methanesulfonic acid 1- ⁇ 5- [5- (4-chloro-phenyl) -pyridin-2-yl-ethynyl] -pyridin-2-yl ⁇ -pyrrolidin-3-yl-ester and 91 mg (0.88 mmol) 4-methoxy-piperidine the product obtained.
  • a solution of 1.00 g (4.72 mmol) of 3- (5-bromo-pyridin-2-yl) -prop-2 is added at -5 ° C. to 4.72 mL (4.72 mmol, 1 M in THF) of a lithium aluminum hydride solution in-1-ol in 25 mL THF is added dropwise so that the internal temperature does not exceed 0 ° C. It is stirred for 2 h. Subsequently, 125 .mu.l of water, 125 .mu.l of 15% sodium hydroxide solution and again 375 .mu.l of water are added. The reaction mixture is filtered, dried over MgS0 and the solvent i.vac. away.
  • the solvent is i.vac. and the residue is taken up with 20 mL EtOAc and 10 mL semisaturated NaHC0 3 solution.
  • the organic phase is dried over Na 2 S0 4 and the solvent i.vac. away.
  • Ansch manend is with
  • reaction mixture is stirred at 0 ° C. for 1 h and at RT for 3 h. It is carefully added
  • the diazonium salt formed is filtered off, washed with cold water, isopropanol and diethyl ether and dried in a desiccator i.vac .. PE (boiling range 100-140 ° C.) is heated to 90 ° C., portions of the The reaction mixture is cooled to RT, made alkaline with saturated Na 2 CO 3 solution and the aqueous phase is exhaustively extracted with TBME The combined organic phases are washed with saturated Na 2 CO 2 3 solution and water and dried over MgS0 After removal of the drying agent and solvent, the residue is dissolved in DCM, filtered through silica gel and the filtrate i.vac. concentrated.
  • a desiccator i.vac .. PE (boiling range 100-140 ° C.) is heated to 90 ° C., portions of the The reaction mixture is cooled to RT, made alkaline with saturated Na 2 CO 3 solution and the aqueous phase is exhaustively extracted with TBME The combined organic phases
  • reaction solution is stirred for 2 h at RT and then 0.50 mL (4.23 mmol) of 4-methylpiperidine are added.
  • the reaction mixture is Stirred for 2 h at RT and then diluted with 30 mL DCM.
  • the organic phase is washed three times with water, dried over MgS0 and the solvent i.vac. away. Further purification is carried out by column chromatography on silica gel (DCM to DCM / MeOH / NH 9: 1: 0.1).
  • reaction solution is brought to RT and stirred for 1 h. It is mixed with ice water, the organic phase is separated, it is washed several times with water and dried over MgS0. 4 After removal of the drying agent and solvent, the residue is purified by chromatography (silica gel, gradient PE to PE / DCM 1: 4)
  • the reaction mixture is stirred for 30 min and then 200 ml of a 1 M sodium hydroxide solution are added with ice cooling. After one hour, the aqueous phase with 300 mL Extracted diethyl ether. The organic phase is dried over Na 2 S0 4 and the solvent i.vac. reduced to 400 mL. The organic phase is washed with 180 ml of saturated Na 2 SO 3 solution and washed twice with 400 ml each of 0.05 M hydrochloric acid solution. The aqueous phase is made alkaline with 30% sodium hydroxide solution and extracted with 400 mL DCM. The combined organic extracts are dried over MgS0 and the solvent i.vac. away. The crude product is reacted further without further purification.
  • Reaction mixture is stirred for 24 h at 80 ° C, the solvent is i.vac. removed and the
  • the residue is mixed with 5.0 mL of 40% methylamine and 5.0 mL of toluene and stirred in a closed vessel at 60 ° C for 3 days.
  • the reaction mixture is diluted with 120 mL DCM.
  • the organic phase is extracted three times with water, dried over MgS0 4 and the solvent i.vac. away.
  • the residue is stirred with TBME and EtOAc and dried after filtration in air.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EP05732062A 2004-04-14 2005-04-08 Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel Withdrawn EP1737824A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004017930A DE102004017930A1 (de) 2004-04-14 2004-04-14 Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
PCT/EP2005/003686 WO2005103032A2 (de) 2004-04-14 2005-04-08 Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
EP1737824A2 true EP1737824A2 (de) 2007-01-03

Family

ID=34964523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05732062A Withdrawn EP1737824A2 (de) 2004-04-14 2005-04-08 Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel

Country Status (9)

Country Link
EP (1) EP1737824A2 (https=)
JP (1) JP2007532596A (https=)
AR (1) AR048691A1 (https=)
CA (1) CA2558755A1 (https=)
DE (1) DE102004017930A1 (https=)
PE (1) PE20060254A1 (https=)
TW (1) TW200538102A (https=)
UY (1) UY28852A1 (https=)
WO (1) WO2005103032A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
KR20090047542A (ko) 2006-08-25 2009-05-12 베링거 인겔하임 인터내셔날 게엠베하 Ｍｃｈ 길항 활성을 갖는 신규한 피리돈 유도체 및 당해 화합물을 포함하는 의약
TW200831485A (en) 2006-12-11 2008-08-01 Boehringer Ingelheim Int New pyridazine derivatives with MCH antagonistic activity and medicaments comprising these compounds
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012007560A1 (en) * 2010-07-16 2012-01-19 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AU2014368619B2 (en) 2013-12-19 2018-11-22 Idorsia Pharmaceuticals Ltd Antibacterial 1H-indazole and 1H-indole derivatives
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
CN110088089B (zh) 2016-10-25 2023-08-29 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
US10125101B2 (en) 2016-11-28 2018-11-13 Boehringer Ingelheim International Gmbh Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7050792B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3573959B1 (en) 2017-01-26 2021-07-28 Boehringer Ingelheim International GmbH Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110214135B (zh) 2017-01-26 2023-02-21 勃林格殷格翰国际有限公司 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1285651B1 (en) * 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
JP2004516239A (ja) * 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
JP2002167382A (ja) * 2000-07-13 2002-06-11 Sankyo Co Ltd アミノアルコ−ル誘導体
GB0119474D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005103032A2 *

Also Published As

Publication number Publication date
PE20060254A1 (es) 2006-03-31
AR048691A1 (es) 2006-05-17
UY28852A1 (es) 2005-11-30
DE102004017930A1 (de) 2005-11-03
WO2005103032A2 (de) 2005-11-03
JP2007532596A (ja) 2007-11-15
CA2558755A1 (en) 2005-11-03
TW200538102A (en) 2005-12-01
WO2005103032A3 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
EP1737824A2 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
EP1558567B1 (de) Neue amid-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
WO2004039780A1 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
US20070111981A1 (en) New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10238865A1 (de) Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20120010185A1 (en) New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds
EP1737823A2 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
US20040209865A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20040152742A1 (en) Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
EP1737839A1 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
US20050245529A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7605176B2 (en) β-ketoamide compounds with MCH antagonistic activity
DE10360745A1 (de) Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1730130A1 (de) Beta-ketoamid-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
EP1740572A1 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
EP1742939A2 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
US20050267120A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US20050239826A1 (en) Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20070129

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100622